$MDVX to Attend the 1st EFIC(R) Topical Symposium 2016


Medovex Corporation to Attend the 1st EFIC(R) Topical Symposium 2016, Acute and Chronic Joint Pain

Medovex Corp. ( NASDAQ : MDVX ), a developer of medical technology products, today announced that the Company will attend the 1st EFIC Topical Symposium, Acute and Chronic Joint Pain being held in Dubrovnik September 21-23.

The event is the EFIC’s first topical seminar on the theme of acute and chronic joint pain. 2016 is the European and global year against joint pain. The meeting in Dubrovnik will bring together clinical scientists and practicing health care workers from all disciplines to consider the many recent developments in the understanding and treatment of joint diseases causing pain and the overall management of such pain.

Topics covered in the Symposium will include animal models of joint pain, inflammatory hyperalgesia, epidemiology and assessment of joint pain, back pain and the new NICE guidelines, acute joint pain and its management including pre and postoperative pain treatment, and all aspects of treatment of chronic joint pain now and in the future.

“We look forward to attending this new symposium as it clearly aligns with the mission of our patented DenerveX™ System, intended to treat Facet Joint Syndrome (FJS), a condition in which the joints in the back of the spine degenerate and subsequently cause pain. Lower back pain is the second most common cause of disability in the U.S. for adults. Studies indicate that 10% of the U.S. adult population suffers from lower back pain and that 31% of lower back pain is attributed to FJS pain,” said Manfred Sablowski, Medovex Senior Vice President Global Sales & Marketing.

The DenerveX System consists of the DenerveX device, a single use medical device and the DenerveX Pro-40 Power Generator, both designed to be less invasive with faster recovery time than current surgical treatment options. It consists of two procedures combined into one device and is expected to provide for a longer lasting treatment solution while offering potential savings to the health care system. DenerveX system is not yet CE marked or FDA cleared and is not yet commercially available.

About Medovex
Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company’s first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com

Safe Harbor Statement
Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the Securities and Exchange Commission (the “SEC”), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.


Please enter your comment!
Please enter your name here